Collagen Peptides Modulating OSCAR Receptor Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone disorders related to osteoclast activity imbalances, such as osteopetrosis and osteoporosis, lack effective modulators for osteoclast differentiation and activation, and existing therapies do not specifically target the osteoclast-associated receptor (OSCAR) pathway.
Innovation Solution
Collagen peptides that bind to the osteoclast-associated receptor (OSCAR) are used to modulate the differentiation and activation of OSCAR-expressing cells, providing a method for treating bone defects and disorders by stimulating or inhibiting OSCAR-mediated signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for bone disorders, then treatment is provided, but they do not specifically target the OSCAR pathway and lack effective modulators for osteoclast differentiation and activation
Solution Approach 1:
The invention segments the collagen molecule into specific peptides (such as GPOGPAGFOGAO and GAOGPAGFA) that contain the OSCAR-binding motif. This segmentation allows the identification and isolation of the specific active region that binds to OSCAR, providing targeted therapy without requiring the entire collagen molecule.
Solution Approach 2:
The collagen peptide acts as an intermediary molecule that specifically binds to the OSCAR receptor on osteoclasts. By using this natural ligand or its mimetics, the invention provides a targeted modulator that mediates the interaction between the therapeutic agent and the OSCAR pathway, enabling specific treatment of bone disorders.
2Adaptability or versatility
If collagen peptides binding to OSCAR are used, then specific modulation of osteoclast differentiation and activation is achieved, but this represents a new targeted approach rather than existing therapy
Solution Approach 1:
The invention changes the parameter of molecular specificity by using collagen peptides with specific amino acid sequences (such as GPOGPAGFOGAO) that match the OSCAR binding motif. This parameter change from non-specific collagen to specific peptide sequences enables targeted binding to OSCAR while maintaining the natural ligand-receptor interaction.
Solution Approach 2:
The invention creates simplified copies or mimetics of the natural collagen-OSCAR interaction. By identifying the critical binding motif within collagen and creating peptide versions (such as GPOGPAGFOGAO or GAOGPAGFA), the invention reproduces the essential therapeutic effect while using a more targeted and controllable molecule.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The collagen peptides enhance or inhibit osteoclastogenesis, effectively treating bone-related disorders by specifically targeting the OSCAR pathway, thereby improving bone turnover and repair.
Implementation Method 1
Collagen is the ligand of the osteoclast-associated receptor (OSCAR), and that OSCAR binding by collagen peptides stimulates the activation and/or differentiation of OSCAR expressing cells
Data Source
AI summary
This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OSCAR expressing cells.